WO2002052015A3 - Self-replicating rna molecule from hepatitis c virus - Google Patents

Self-replicating rna molecule from hepatitis c virus Download PDF

Info

Publication number
WO2002052015A3
WO2002052015A3 PCT/CA2001/001843 CA0101843W WO02052015A3 WO 2002052015 A3 WO2002052015 A3 WO 2002052015A3 CA 0101843 W CA0101843 W CA 0101843W WO 02052015 A3 WO02052015 A3 WO 02052015A3
Authority
WO
WIPO (PCT)
Prior art keywords
hcv
self
replication
replicating
mutations
Prior art date
Application number
PCT/CA2001/001843
Other languages
French (fr)
Other versions
WO2002052015A2 (en
Inventor
George Kukolj
Arnim Pause
Original Assignee
Boehringer Ingelheim Ca Ltd
George Kukolj
Arnim Pause
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Ca Ltd, George Kukolj, Arnim Pause filed Critical Boehringer Ingelheim Ca Ltd
Priority to AU2002218906A priority Critical patent/AU2002218906B2/en
Priority to NZ527035A priority patent/NZ527035A/en
Priority to CA002430607A priority patent/CA2430607C/en
Priority to IL15605801A priority patent/IL156058A0/en
Priority to HU0302593A priority patent/HU229567B1/en
Priority to JP2002553495A priority patent/JP2004516039A/en
Priority to EP01271930A priority patent/EP1379660B1/en
Priority to DE60128835T priority patent/DE60128835T2/en
Priority to MXPA03005638A priority patent/MXPA03005638A/en
Publication of WO2002052015A2 publication Critical patent/WO2002052015A2/en
Publication of WO2002052015A3 publication Critical patent/WO2002052015A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24241—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

A unique HCV RNA molecule is provided having an enhanced efficiency of establishing cell culture replication. Novel adaptive mutations have been identified within the HCV non-structural region that improves the efficiency of establishing persistently replicating HCV RNA in cell culture. This self-replicating polynucleotide molecule contains, contrary to all previous reports, a 5'-NTR that can be either an A as an alternative to the G already disclosed and therefore provides an alternative to existing systems comprising a self-replicating HCV RNA molecule. The G-->A mutation gives rise to HCV RNA molecules that, in conjunction with mutations in the HCV non-structural region, such as the G(2042)C/R mutations, possess greater efficiency of transduction and/or replication. These RNA molecules when transfected in a cell line are useful for evaluating potential inhibitors of HCV replication.
PCT/CA2001/001843 2000-12-22 2001-12-20 Self-replicating rna molecule from hepatitis c virus WO2002052015A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AU2002218906A AU2002218906B2 (en) 2000-12-22 2001-12-20 Self-replicating RNA molecule from hepatitis C virus
NZ527035A NZ527035A (en) 2000-12-22 2001-12-20 Self-replicating RNA molecule from hepatitis C virus
CA002430607A CA2430607C (en) 2000-12-22 2001-12-20 Self-replicating rna molecule from hepatitis c virus
IL15605801A IL156058A0 (en) 2000-12-22 2001-12-20 Self-replicating rna molecule from hepatitis c virus
HU0302593A HU229567B1 (en) 2000-12-22 2001-12-20 Self-replicating rna molecule from hepatitis c virus
JP2002553495A JP2004516039A (en) 2000-12-22 2001-12-20 Self-replicating RNA molecule from hepatitis C virus
EP01271930A EP1379660B1 (en) 2000-12-22 2001-12-20 Self-replicating rna molecule from hepatitis c virus
DE60128835T DE60128835T2 (en) 2000-12-22 2001-12-20 SELF-REPLICATING RNA MOLECULAR FROM HEPATITIS C VIRUS
MXPA03005638A MXPA03005638A (en) 2000-12-22 2001-12-20 Self-replicating rna molecule from hepatitis c virus.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25785700P 2000-12-22 2000-12-22
US60/257,857 2000-12-22

Publications (2)

Publication Number Publication Date
WO2002052015A2 WO2002052015A2 (en) 2002-07-04
WO2002052015A3 true WO2002052015A3 (en) 2003-11-20

Family

ID=22978064

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2001/001843 WO2002052015A2 (en) 2000-12-22 2001-12-20 Self-replicating rna molecule from hepatitis c virus

Country Status (13)

Country Link
US (5) US6706874B2 (en)
EP (1) EP1379660B1 (en)
JP (2) JP2004516039A (en)
AT (1) ATE364085T1 (en)
AU (1) AU2002218906B2 (en)
CA (1) CA2430607C (en)
DE (1) DE60128835T2 (en)
ES (1) ES2287074T3 (en)
HU (1) HU229567B1 (en)
IL (1) IL156058A0 (en)
MX (1) MXPA03005638A (en)
NZ (1) NZ527035A (en)
WO (1) WO2002052015A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040005549A1 (en) * 2000-11-07 2004-01-08 Anadys Pharmaceuticals, Inc. Hepatitis C virus constructs characterized by high efficiency replication
AU2002225895A1 (en) * 2000-11-07 2002-05-21 Anadys Pharmaceuticals, Inc. Hepatitis c virus constructs characterized by high efficiency replication
AU2002218906B2 (en) * 2000-12-22 2006-08-03 Boehringer Ingelheim (Canada) Ltd. Self-replicating RNA molecule from hepatitis C virus
JP4299540B2 (en) * 2001-01-23 2009-07-22 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー Hepatitis C virus replicon and replicon enhanced cells
WO2003089672A1 (en) * 2002-04-16 2003-10-30 Merck & Co., Inc. Hepatitis c virus assay systems
NZ540292A (en) * 2002-10-29 2006-09-29 Boehringer Ingelheim Int Novel inhibitor-resistant HCV NS3 protease comprising a mutated amino acid sequence
ATE452192T1 (en) 2003-02-13 2010-01-15 Merck & Co Inc METHOD FOR PROVIDING CELL CULTURE REPLICATION ACTIVITY TO DIFFERENT HEPATITIS C VIRUS ISOLATES
EP1685238A4 (en) 2003-11-05 2008-08-20 Merck & Co Inc Hcv replicons containing ns5b from genotype 2b
US20070128625A1 (en) * 2005-07-25 2007-06-07 Gilead Sciences, Llc Drug-resistant mutants of hepatitis C virus
EP1801116A1 (en) * 2005-12-21 2007-06-27 F. Hoffmann-La Roche Ag HCV replicon shuttle vectors
US8454974B2 (en) 2007-04-13 2013-06-04 Hvidovre Hospital Adaptive mutations allow establishment of JFH1-based cell culture systems for hepatitis C virus genotype 4A
US8945584B2 (en) 2007-04-13 2015-02-03 Hvidovre Hospital Cell culture system of a hepatitis C genotype 3a and 2a chimera
US8618275B2 (en) 2007-05-18 2013-12-31 Hvidovre Hospital Efficient cell culture system for hepatitis C virus genotype 5A
GB0716292D0 (en) 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
US8569472B2 (en) 2007-12-20 2013-10-29 Hvidovre Hospital Efficient cell culture system for hepatitis C virus genotype 6A
KR100945784B1 (en) 2008-01-24 2010-03-08 한국외국어대학교 연구산학협력단 The HCV treatment material inhibiting polymerase NS5B of HCV
US8506969B2 (en) 2008-08-15 2013-08-13 Hvidovre Hospital Efficient cell culture system for hepatitis C virus genotype 7a
US8663653B2 (en) 2008-08-15 2014-03-04 Hvidovre Hospital Efficient cell culture system for hepatitis C virus genotype 2B
US8772022B2 (en) 2008-10-03 2014-07-08 Hvidovre Hospital Hepatitis C virus expressing reporter tagged NS5A protein
US20100173281A1 (en) * 2009-01-06 2010-07-08 Roche Palo Alto Llc HCV NS3 protease replicon shuttle vectors
US9775894B2 (en) 2013-07-09 2017-10-03 University Of Washington Through Its Center For Commercialization Methods and compositions for activation of innate immune responses through RIG-I like receptor signaling

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1043399A2 (en) * 1999-04-03 2000-10-11 Ralf Dr. Bartenschlager Hepatitis C Virus cell culture system

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127116A (en) * 1995-08-29 2000-10-03 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
US5693434A (en) * 1996-07-22 1997-12-02 Motorola, Inc. Electrochemical cell having a polymer electrolyte
DK1177211T3 (en) * 1999-05-04 2008-06-02 Boehringer Ingelheim Ca Ltd Surrogate cell-based system and method for analyzing the activity of Hepatitis C virus NS3 protease
EP1296998B1 (en) * 2000-05-23 2011-09-21 Washington University Hcv variants
AU2002218906B2 (en) * 2000-12-22 2006-08-03 Boehringer Ingelheim (Canada) Ltd. Self-replicating RNA molecule from hepatitis C virus
US6689559B2 (en) * 2001-11-29 2004-02-10 The Research Foundation Of The State University Of New York Efficient hepatitis C virus replicon and its use in identifying antiviral compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1043399A2 (en) * 1999-04-03 2000-10-11 Ralf Dr. Bartenschlager Hepatitis C Virus cell culture system

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BLIGHT K J ET AL: "EFFICIENT INITIATION OF HCV RNA REPLICATION IN CELL CULTURE", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 290, 8 December 2000 (2000-12-08), pages 1972 - 1974, XP002951271, ISSN: 0036-8075 *
LOHMANN V ET AL: "Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line.", SCIENCE (WASHINGTON D C), vol. 285, no. 542, 2 July 1999 (1999-07-02), pages 110 - 113, XP002232924, ISSN: 0036-8075 *

Also Published As

Publication number Publication date
EP1379660A2 (en) 2004-01-14
US6956117B2 (en) 2005-10-18
WO2002052015A2 (en) 2002-07-04
US6706874B2 (en) 2004-03-16
CA2430607C (en) 2009-12-01
DE60128835T2 (en) 2008-03-20
NZ527035A (en) 2006-02-24
US20060246424A1 (en) 2006-11-02
HU229567B1 (en) 2014-02-28
JP2006304803A (en) 2006-11-09
US7344723B2 (en) 2008-03-18
IL156058A0 (en) 2003-12-23
MXPA03005638A (en) 2004-04-05
US20030148348A1 (en) 2003-08-07
EP1379660B1 (en) 2007-06-06
CA2430607A1 (en) 2002-07-04
US20040203020A1 (en) 2004-10-14
ES2287074T3 (en) 2007-12-16
US20040180333A1 (en) 2004-09-16
US20020142350A1 (en) 2002-10-03
HUP0302593A3 (en) 2012-09-28
ATE364085T1 (en) 2007-06-15
HUP0302593A2 (en) 2003-10-28
JP2004516039A (en) 2004-06-03
AU2002218906B2 (en) 2006-08-03
US7919312B2 (en) 2011-04-05
DE60128835D1 (en) 2007-07-19

Similar Documents

Publication Publication Date Title
WO2002052015A3 (en) Self-replicating rna molecule from hepatitis c virus
Borman et al. Picornavirus internal ribosome entry segments: comparison of translation efficiency and the requirements for optimal internal initiation of translation in vitro
CA2220873A1 (en) Method for reproducing in vitro the rna-dependent rna polymerase and terminal nucleotidyl transferase activities encoded by hepatitis c virus (hcv)
EP2281897A3 (en) Oncolytic mutant Herpes Simplex virus
DE69534855D1 (en) ENZYMMETIVE DNA MOLECULES
HUP0203305A2 (en) Infectious clones
FI955224A (en) Hepatitis C virus types 4.5 and 6
ID27760A (en) POLYCETIDES, THEIR PRODUCTION, AND INGREDIENTS FOR USE
AU9123598A (en) High fidelity polymerases and uses thereof
WO2004018506A3 (en) Inducible alphaviral/orip based gene expression system
KR927003822A (en) Virus / herbicide-tolerant genes, methods for their preparation and uses thereof
WO1994000572A3 (en) Gene for ataxia-telangiectasia complementation group d (atdc)
CA2037677A1 (en) Process for production of exogenous gene or its product in plant cells
ATE60360T1 (en) PROBE AND METHODS FOR THE DETECTION OF CERTAIN MICROORGANISMS, NAMELY LEGIONELLA, IN MEDIA CONTAINING THESE.
ATE408013T1 (en) INFECTIOUS CDNA CLONE OF GB VIRUS B AND ITS USES
EP0647280A4 (en) Over expression of single-stranded molecules.
DE60213578D1 (en) REPLICATION PROCESS OF HEPATITIS C VIRUS
WO1997008531A3 (en) Detection of hepatitis gb virus genotypes
DK0906430T3 (en) Biosynthesis procedure which enables production of O-phospho-L-threonine
ATE215604T1 (en) PRODUCTION OF POLYMERS FROM NUCLEOTIDIC AND/OR NON-NUCLEOTIDIC BUILDING BLOCKS BY ENZYMATIC WAYS
MD2149G2 (en) Oligonucleotide primer for hepatitis C virus RNA detection
AUPO023496A0 (en) Modified small RNA viruses
KR960014360A (en) Transformed plant cell selection method using animal gene
George et al. Cytochrome P 450 biotechnology for toxicological studies of pollutants
AU8013798A (en) Yeast cells comprising at least two copies of a desired gene integrated into thechromosomal genome at more than one non-ribosomal rna encoding domain, particul arly with kluyveromyces

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 156058

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2430607

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001271930

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/005638

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2002553495

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002218906

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 527035

Country of ref document: NZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001271930

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 527035

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 2001271930

Country of ref document: EP